September 18, 2008 – Boca Raton, FL – Lexington International, LLC, manufacturer and developer of the HairMax LaserComb® is pleased to welcome Dr. Michael Hamblin to its Scientific Advisory Board. Dr. Hamblin will provide professional expertise and guide Lexington in further understanding the biological mechanism of Photodynamic Therapy. In addition, Dr Hamblin will help Lexington model optimum energy parameters and assist in developing the most advanced and effective skincare devices for the consumer mass market.
Dr. Hamblin, a premier expert in the field of laser phototherapy, obtained his Ph.D. degree in 1977 from Nottingham Trent University in England. Dr. Hamblin is a principal investigator at Wellman Center of Photomedicine at Massachusetts General Hospital and an Associate Professor at Harvard Medical School. Dr. Hamblin’s primary research interests cover applications of photodynamic therapy to cancer, infections and heart disease, and the use of low-level light therapy for wound healing, hair regrowth, inflammatory disorders, and brain damage. To date, Dr. Hamblin has authored or co-authored 86 peer-reviewed scientific research papers, filed over 12 U.S. patent applications, and given over 50 invited lectures in North America, Europe, and Asia. Dr. Hamblin chairs an annual conference at SPIE Photonics West BiOS meeting in San Jose, CA entitled “Mechanisms for Low Level Light Therapy”.
Lexington is further expanding its home-use device market presence to include light phototherapy devices for skin care. The skin care device market is rapidly expanding and Lexington is poised to develop new skin care devices utilizing phototherapy technology. Lexington believes its key to success with these new skin care devices will be to develop, with Dr Hamblin’s guidance, devices with optimal technical specifications and cutting-edge design both of which will ultimately provide positive user experiences.
Dr. Hamblin states, “We have demonstrated, in both clinical and laboratory settings, the benefits of photodynamic therapy (combination of non-toxic dyes and visible light), and photobiomodulation (stimulation of tissue by light alone). I believe light therapy has a great deal of utility to the general public, and I look forward to working with Lexington to provide advice on low level laser and other light therapy technology.”
Co-founder and Managing Director of Lexington International, LLC, David Michaels said, “We are excited to have Dr. Hamblin, a key authoritative figure in the field of light therapy, available for advice and guidance to help Lexington maintain leadership in the low-level laser hair growth sector, and assist in our home use, skin care device development. The addition of Dr. Hamblin to our Medical Advisory Board reaffirms our commitment to continued research and contributions to the science behind light therapy devices for consumer use.”